Nuvation Bio's IBTROZI Revenue Hits $18.5M, Clinical Data Shows 'Unprecedented Durability'
NUVB has more than doubled off its 52-week low of $1.57.
Summary
Nuvation Bio reported strong first-quarter 2026 financial results, achieving $18.5 million in net product revenues for IBTROZI, demonstrating significant commercial momentum for its lead oncology product. The company also presented highly positive updated clinical data at AACR 2026, showcasing 'unprecedented durability' for IBTROZI with a median duration of response of 49.7 months and progression-free survival of 46.1 months in TKI-naïve patients. This robust data, coupled with the acquisition of global development and commercialization rights for safusidenib, expands Nuvation Bio's pipeline and future growth prospects. Additionally, IBTROZI's inclusion in NCCN Guidelines for CNS cancers and the EMA's validation of its Marketing Authorisation Application are key milestones for market adoption and international expansion. The company's strong balance sheet, with $533.7 million in cash, provides substantial financial flexibility. Investors will be watching for continued IBTROZI sales growth, progress on safusidenib's Phase 3 study, and updates on their drug-drug conjugate platform.
At the time of this announcement, NUVB was trading at $4.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.57 to $9.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.